Hepion Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Hepion Pharmaceuticals est Bob Foster, nommé en Jun2016, a un mandat de 7.17 ans. La rémunération annuelle totale est $ 725.83K, composée du salaire de 73.5% et des bonus 26.5%, y compris les actions et options de la société. détient directement 0.062% des actions de la société, d'une valeur de € 16.40K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.8 ans et 3.6 ans.

Informations clés

Bob Foster

Directeur général

US$725.8k

Rémunération totale

Pourcentage du salaire du PDG	73.5%
Durée du mandat du directeur général	7.2yrs
Propriété du PDG	0.06%
Durée moyenne d'occupation des postes de direction	3.8yrs
Durée moyenne du mandat des membres du conseil d'administration	3.6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Bob Foster a-t-elle évolué par rapport aux bénéfices de Hepion Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$726k	US$533k	-US$45m
Sep 30 2022	n/a	n/a	-US$45m
Jun 30 2022	n/a	n/a	-US$46m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$700k	US$500k	-US$33m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$2m	US$400k	-US$20m
Sep 30 2020	n/a	n/a	-US$18m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$621k	US$400k	-US$12m
Sep 30 2019	n/a	n/a	-US$12m
Jun 30 2019	n/a	n/a	-US$20m
Mar 31 2019	n/a	n/a	-US$17m
Dec 31 2018	US$375k	US$312k	-US$18m

Rémunération vs marché: La rémunération totale de Bob ($USD 725.83K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 471.14K ).

Rémunération et revenus: La rémunération de Bob a augmenté alors que l'entreprise n'est pas rentable.

PDG

Bob Foster (65 yo)

7.2yrs

Titularisation

US$725,833

Compensation

Dr. Robert T. Foster, also known as Bob, B.Sc (Pharm), Pharm D., Ph D., has been Chief Executive Officer at Hepion Pharmaceuticals, Inc. (formerly ContraVir Pharmaceuticals, Inc.) since October 3, 2018, Di...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Robert Foster	President	7.2yrs	US$725.83k	0.062% € 16.4k
John Cavan	Chief Financial Officer	7.4yrs	US$495.33k	0.020% € 5.2k
Todd Hobbs	Chief Medical Officer	2.5yrs	US$578.00k	pas de données
Launa Aspeslet	Chief Operating Officer	1.2yrs	pas de données	pas de données
Sharen Pyatetskaya	Director of Investor Relations	no data	pas de données	pas de données
Daniel Trepanier	Senior Vice President of Drug Development	3.8yrs	pas de données	pas de données
Patrick Mayo	Senior Vice President of Clinical Pharmacology	3.8yrs	pas de données	pas de données
John Sullivan-Bolyai	Part-Time Consultant	5.7yrs	US$34.62k	pas de données
Stephen Harrison	Scientific Advisory Board Chair & Consultant Medical Director	3.8yrs	pas de données	pas de données

3.8yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 336 est considérée comme expérimentée (ancienneté moyenne 3.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Robert Foster	President	4.8yrs	US$725.83k	0.062% € 16.4k
Stephen Harrison	Scientific Advisory Board Chair & Consultant Medical Director	4yrs	pas de données	pas de données
John Brancaccio	Independent Director	10.3yrs	US$86.00k	0.0092% € 2.4k
Gary Jacob	Independent Chairman of the Board	10.3yrs	US$102.50k	0.016% € 4.2k
Timothy M. Block	Independent Director	9.8yrs	US$77.90k	pas de données
Petrus L. Wijngaard	Independent Director	3.2yrs	US$79.50k	0.039% € 10.4k
Rohit Loomba	Member of Scientific Advisory Board	less than a year	pas de données	pas de données
Nikolai Naoumov	Member of Scientific Advisory Board	less than a year	pas de données	pas de données
Philippe Gallay	Member of Scientific Advisory Board	7.1yrs	pas de données	pas de données
Anand Reddi	Independent Director	1.2yrs	US$30.92k	pas de données
Yury Popov	Member of Scientific Advisory Board	less than a year	pas de données	pas de données
Kaouthar Lbiati	Independent Director	1.2yrs	US$30.92k	pas de données

3.6yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 336 sont considérés comme expérimentés (ancienneté moyenne 3.6 ans).

Hepion Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

High number of new directors

Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022

Recent updates

Hepion Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Stockholder's Deficit

Hepion Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) in a reverse merger transaction valued at an implied equity value of approximately $58.5 million.

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease

Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice

Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding

Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial

High number of new directors

Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma

Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Hepion Pharmaceuticals Receives 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Publication of Phase 2A 'Ambition' Clinical Trial Results

Hepion Pharmaceuticals, Inc. Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022

Hepion Pharmaceuticals, Inc. Announces Board Changes

Hepion Pharmaceuticals, Inc. Appoints Dr. Launa J. Aspeslet as Chief Operating Officer

Hepion Pharmaceuticals Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard from Nasdaq

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2022

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals Appoints Eddie C. Cheung to Lead the Company’s Strategic Medical Affairs in Asia

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer

Hepion Pharmaceuticals, Inc Announces Additional Efficacy Data from Its Phase 2A Ambition Clinical Trial

Hepion Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 2A ‘Ambition’ Nash Trial and Achieve All Primary Endpoints

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2A 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $88.4 million.

Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Hepion Pharmaceuticals Terminated the At Market Issuance Sales Agreement with B. Riley FBR, Inc

New 90-day low: €2.22

Hepion Pharmaceuticals, Inc.'s Data Safety Monitoring Board Recommends Continuation of Phase 2A 'Ambition' Clinical Trial for Treatment of Advanced Nash

New 90-day low: €2.44

Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development

Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases

New 90-day high - €3.76

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen